Drug intelligence / Profile preview

tumor mRNA vaccine

Development stage: Preclinical
Lead developer: Changchun BCHT Biotechnology
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular, Subcutaneous

Overview

The tumor mRNA vaccine is a therapeutic cancer vaccine candidate currently in preclinical development by Changchun BCHT Pharmaceutical. This vaccine utilizes mRNA technology to deliver genetic instructions encoding tumor-associated antigens into the patient's cells. Once translated, these antigens are presented to the immune system to stimulate a targeted immune response, specifically activating T-cells to recognize and eliminate cancer cells. The program aims to provide a novel immunotherapy approach for the treatment of various malignant tumors.

Other names: 肿瘤mRNA疫苗BCHT tumor mRNA vaccine

Beyond the preview

Go deeper on tumor mRNA vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tumor mRNA vaccine.

Explore the full profile